Nymox Pharmaceutical Revenue Growth Rates (NYMX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nymox Pharmaceutical Corporation  (NYMX)
 

NYMX's Revenue Growth by Quarter and Year

Nymox Pharmaceutical's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NYMX Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 0.00
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 0.00

NYMXs Annual Revenue
Nymox Pharmaceutical's Revenue in the fiscal year 2024 $ 0.00 millions
Nymox Pharmaceutical's Revenue in the fiscal year 2023 $ 0.00 millions
Nymox Pharmaceutical's Revenue in the fiscal year 2022 $ 0.00 millions
Nymox Pharmaceutical's Revenue in the fiscal year 2021 $ 0.00 millions
Nymox Pharmaceutical's Revenue in the fiscal year 2020 $ 0.01 millions




NYMX Revenue fourth quarter 2024 Y/Y Growth Comment
Nymox Pharmaceutical Corporation in the fourth quarter 2024 recorded of $ 0.00 millions.

According to the results reported in the fourth quarter 2024, Nymox Pharmaceutical Corporation achieved the best Revenue growth in In Vitro & In Vivo Diagnostic Substances industry. While Nymox Pharmaceutical Corporation' s Revenue no change of 0% ranks overall at the positon no. in the fourth quarter 2024.


NYMX Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Nymox Pharmaceutical's fourth quarter 2024 Revenue $ 0.00 millions NYMX's Income Statement
Nymox Pharmaceutical's fourth quarter 2023 Revenue $ 0.00 millions Quarterly NYMX's Income Statement


NYMX Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Back to NYMX Growth rate Comparisons >> Back to NYMX Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Nymox Pharmaceutical's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NYMX's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NYMX's IV. Quarter Q/Q Revenue Comment


Nymox Pharmaceutical's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Dec 31 2020)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.01
Y / Y Revenue Growth (TTM) - - - - -95.69 %
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -95.69 %
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Dec 31 2024 period, Nymox Pharmaceutical's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 633 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 14
Healthcare Sector # 634
Overall # 4568

Revenue TTM Y/Y Growth Statistics
High Average Low
33.48 %
 -41.14 %
-95.69 %
(Dec 31 2018)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 634
S&P 500 # 4568
Cumulative Revenue growth Comment
In the Dec 31 2024 period, Nymox Pharmaceutical's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 633 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 14
Healthcare Sector # 634
Overall # 4568

Revenue TTM Y/Y Growth Statistics
High Average Low
33.48 %
-41.14 %
-95.69 %
(Dec 31 2018)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 634
S&P 500 # 4568




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NYMX's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Dec 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2024
Adapthealth Corp -0.19%$ -0.185 millions
Bioaffinity Technologies Inc -0.26%$ -0.260 millions
Organon and Co -0.38%$ -0.375 millions
Royalty Pharma Plc-0.41%$ -0.407 millions
Carlisle Companies Incorporated-0.41%$ -0.408 millions
Silo Pharma Inc-0.41%$ -0.409 millions
Shl Telemedicine Ltd-0.52%$ -0.519 millions
Cytek Biosciences Inc -0.59%$ -0.586 millions
Kronos Bio Inc -0.70%$ -0.700 millions
Koninklijke Philips Nv-0.81%$ -0.815 millions
Enhabit Inc -0.92%$ -0.921 millions
Charles River Laboratories International inc -1.08%$ -1.078 millions
Elanco Animal Health Incorporated-1.45%$ -1.449 millions
Illumina Inc -1.60%$ -1.604 millions
Perrigo Company Plc-1.62%$ -1.616 millions
Fonar Corporation-1.72%$ -1.717 millions
Quipt Home Medical Corp -1.90%$ -1.905 millions
Bio rad Laboratories Inc -1.91%$ -1.910 millions
Surmodics Inc -2.06%$ -2.062 millions
Avantor Inc -2.10%$ -2.101 millions
Petvivo Holdings Inc -2.11%$ -2.111 millions
Iridex Corp-2.15%$ -2.153 millions
Assertio Holdings inc -2.43%$ -2.431 millions
Apyx Medical Corp-2.58%$ -2.578 millions
Bioxcel Therapeutics Inc -2.66%$ -2.660 millions
Zynex inc -2.66%$ -2.665 millions
Nrc Health-2.88%$ -2.879 millions
Teladoc Health Inc -3.03%$ -3.033 millions
Orchestra Biomed Holdings Inc -3.44%$ -3.435 millions
Xenetic Biosciences Inc -3.45%$ -3.449 millions


About Nymox Pharmaceutical Revenue Growth Rates (NYMX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nymox Pharmaceutical Corp (CIK 1018735).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001640334-25-000972
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nymox Pharmaceutical Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.